208 related articles for article (PubMed ID: 29039762)
21. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
[TBL] [Abstract][Full Text] [Related]
22. Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate.
Lindberg MF; Deau E; Miege F; Greverie M; Roche D; George N; George P; Merlet L; Gavard J; Brugman SJT; Aret E; Tinnemans P; de Gelder R; Sadownik J; Verhofstad E; Sleegers D; Santangelo S; Dairou J; Fernandez-Blanco Á; Dierssen M; Krämer A; Knapp S; Meijer L
J Med Chem; 2023 Dec; 66(23):15648-15670. PubMed ID: 38051674
[TBL] [Abstract][Full Text] [Related]
23. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
[TBL] [Abstract][Full Text] [Related]
24. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
25. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
27. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Pathak A; Rohilla A; Gupta T; Akhtar MJ; Haider MR; Sharma K; Haider K; Yar MS
Eur J Med Chem; 2018 Oct; 158():559-592. PubMed ID: 30243157
[TBL] [Abstract][Full Text] [Related]
28. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
Rosenthal AS; Tanega C; Shen M; Mott BT; Bougie JM; Nguyen DT; Misteli T; Auld DS; Maloney DJ; Thomas CJ
Bioorg Med Chem Lett; 2011 May; 21(10):3152-8. PubMed ID: 21450467
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
30. Design of granulatimide and isogranulatimide analogues as potential Chk1 inhibitors: Study of amino-platforms for their synthesis.
Lavrard H; Rodriguez F; Delfourne E
Bioorg Med Chem; 2014 Sep; 22(17):4961-7. PubMed ID: 25047935
[TBL] [Abstract][Full Text] [Related]
31. Unprecedented one-pot chemocontrolled entry to thioxoimidazolidinones and aminoimidazolones: synthesis of kinase inhibitor leucettamine B.
Selvaraju M; Sun CM
ACS Comb Sci; 2015 Mar; 17(3):182-9. PubMed ID: 25569559
[TBL] [Abstract][Full Text] [Related]
32. Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases.
Shen S; Liu D; Wei C; Proksch P; Lin W
Bioorg Med Chem; 2012 Dec; 20(24):6924-8. PubMed ID: 23131412
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Masaki S; Kii I; Sumida Y; Kato-Sumida T; Ogawa Y; Ito N; Nakamura M; Sonamoto R; Kataoka N; Hosoya T; Hagiwara M
Bioorg Med Chem; 2015 Aug; 23(15):4434-4441. PubMed ID: 26145823
[TBL] [Abstract][Full Text] [Related]
34. Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.
Van Voorhis WC; Doggett JS; Parsons M; Hulverson MA; Choi R; Arnold SLM; Riggs MW; Hemphill A; Howe DK; Mealey RH; Lau AOT; Merritt EA; Maly DJ; Fan E; Ojo KK
Exp Parasitol; 2017 Sep; 180():71-83. PubMed ID: 28065755
[TBL] [Abstract][Full Text] [Related]
35. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of dual specificity kinase activity of DYRK1A.
Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
[TBL] [Abstract][Full Text] [Related]
38. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the SR protein-phosphorylating CLK kinases of Plasmodium falciparum impairs blood stage replication and malaria transmission.
Kern S; Agarwal S; Huber K; Gehring AP; Strödke B; Wirth CC; Brügl T; Abodo LO; Dandekar T; Doerig C; Fischer R; Tobin AB; Alam MM; Bracher F; Pradel G
PLoS One; 2014; 9(9):e105732. PubMed ID: 25188378
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of desaza analogues of annomontine and canthin-4-one alkaloids.
Strödke B; Gehring AP; Bracher F
Arch Pharm (Weinheim); 2015 Feb; 348(2):125-31. PubMed ID: 25664630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
